Passenger deletions generate therapeutic vulnerabilities in cancer

Muller, Florian L., Colla, Simona, Aquilanti, Elisa, Manzo, Veronica E., Genovese, Giannicola, Lee, Jaclyn, Eisenson, Daniel, Narurkar, Rujuta, Deng, Pingna, Nezi, Luigi, Lee, Michelle A., Hu, Baoli, Hu, Jian, Sahin, Ergun, Ong, Derrick, Fletcher-Sananikone, Eliot, Ho, Dennis, Kwong, Lawrence, Brennan, Cameron, Wang, Y. Alan, Chin, Lynda, DePinho, Ronald A.·2012·Nature
DOI 10.1038/nature11331

Cited by (344)

Items 201–300 of 344

  1. An essential passenger with p53
    James E. Bradner · 2015 · Nature
  2. Functional and structural basis of E. coli enolase inhibition by SF2312: a mimic of the carbanion intermediate
    J. Krucinska, Michael N. Lombardo, Heidi Erlandsen, Akram Hazeen, Searle S. Duay, Jason G. Pattis, Victoria L. Robinson, Eric R. May, Dennis L. Wright · 2019 · Scientific Reports
  3. Paralogous synthetic lethality underlies genetic dependencies of the cancer-mutated gene STAG2
    Melanie L. Bailey, David D. Tieu, Andrea Habsid, Amy H.Y. Tong, Katherine Chan, Jason Moffat, Philip Hieter · 2021 · Life Science Alliance
  4. Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer
    Zhengnan Huang, Yi‐Lin Yan, Tengjiao Wang, Zeyi Wang, Jinming Cai, Xiangqian Cao, Chenkai Yang, Fang Zhang, Gang Wu, Bing Shen · 2022 · Journal of Translational Medicine
  5. Synthetic lethality: emerging targets and opportunities in melanoma
    Nicola Thompson, David J. Adams, Marco Ranzani · 2017 · Pigment Cell & Melanoma Research
  6. Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas
    Olivier Mauduit, Vanessa Delcroix, Tom Lesluyes, Gaëlle Pérot, Pauline Lagarde, Lydia Lartigue, Jean‐Yves Blay, Frédéric Chibon · 2019 · Cancers
  7. Essential genes shape cancer genomes through linear limitation of homozygous deletions
    Maroulio Pertesi, Ludvig Ekdahl, Angelica A. Palm, Ellinor Johnsson, Linnea Järvstråt, Anna-Karin Wihlborg, Björn Nilsson · 2019 · Communications Biology
  8. Bacteriophage protein PEIP is a potent Bacillus subtilis enolase inhibitor
    Kaining Zhang, Shanshan Li, Zhihao Wang, Zi Wang, Nancy Mulvenna, Hang Yang, Peipei Zhang, Huan Chen, Yan Li, Hongliang Wang et al. · 2022 · Cell Reports
  9. Current therapeutic options for glioblastoma and future perspectives
    Elisa Aquilanti, Patrick Yung Wen · 2022 · Expert Opinion on Pharmacotherapy
  10. In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
    Anna-Katharina Wirth, Lucas Esteban Wange, Sebastian Vosberg, Kai‐Oliver Henrich, Christian R. Rausch, Erbey Ziya Özdemir, Christina Zeller, Daniel Richter, Tobias F. Feuchtinger, Markus Kaller et al. · 2022 · Leukemia
  11. A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
    Verónica Rendo, Michaël Schubert, Nicholas Khuu, Maria F. Suárez Peredo Rodríguez, Declan Whyte, Xiao Ling, Anouk van den Brink, Kaimeng Huang, Michelle L. Swift, Yizhou Joseph He et al. · 2025 · Nature Communications
  12. Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion
    Susumu Kohno, Paing Linn, Naoko Nagatani, Yoshihiro Watanabe, Sharad Kumar, Tomoyoshi Soga, Chiaki Takahashi · 2020 · Oncogene
  13. Critical roles of mitochondria in brain activities of torpid Myotis ricketti bats revealed by a proteomic approach
    Yijian Zhang, Yi-Hsuan Pan, Qiuyuan Yin, Tianxiao Yang, Dong Dong, Chen-Chung Liao, Shuyi Y. Zhang · 2014 · Journal of Proteomics
  14. Rethinking ‘academic’ drug discovery: the Manchester Institute perspective
    Allan Michael Jordan, Ian D. Waddell, Donald Ogilvie · 2014 · Drug Discovery Today
  15. The Role of Chromosome Deletions in Human Cancers
    Mei Chen, Yi Yang, Yu Liu, Chong Chen · 2018 · Advances in experimental medicine and biology
  16. Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics
    Yang Gao, Elena B. Kabotyanski, Elizabeth Villegas, Jonathan H. Shepherd, Deanna Acosta, Clark Hamor, Tingting Sun, Celina Montmeyor-Garcia, Xiaping He, Lacey Elizabeth Dobrolecki et al. · 2021 · Cancer Research Communications
  17. Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers
    Victoria C. Yan, Cong-Dat Pham, Elliot Ballato, Kristine L. Yang, Kenisha Arthur, Sunada Khadka, Yasaman Barekatain, Prakriti Shrestha, Theresa Tammy Tran, Anton H. Poral et al. · 2022 · Journal of Medicinal Chemistry
  18. Seed and soil: A conceptual framework of metastasis for clinicians.
    Farhoud Faraji, Joel C. Eissenberg · 2013 · Europe PMC (PubMed Central)
  19. Paralog dispensability shapes homozygous deletion patterns in tumor genomes
    Barbara De Kegel, Colm J. Ryan · 2023 · Molecular Systems Biology
  20. RIOK1 kinase activity is required for cell survival irrespective ofMTAPstatus
    Alexandra Hörmann, Barbara Hopfgartner, Thomas Köcher, Maja Corcokovic, Teresa Krammer, Christoph Reiser, Gerd Bader, Junwei Shi, Katharina Ehrenhöfer, Simon Wöhrle et al. · 2018 · Oncotarget
  21. Identification of α-enolase as a prognostic and diagnostic precancer biomarker in oral submucous fibrosis
    Swarnendu Bag, Debabrata Dutta, Amrita Chaudhary, Bidhan Chandra Sing, Mousumi Pal, Ajoy Kumar Ray, Rita Banerjee, Ranjan Rashmi Paul, Amit Basak, Amit Kumar Das et al. · 2017 · Journal of Clinical Pathology
  22. Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1
    Marie E. Beckner, Ian F. Pollack, Mary Lowery Nordberg, Ronald L. Hamilton · 2015 · BBA Clinical
  23. Paralog-based synthetic lethality: rationales and applications
    Yucui Xin, Yingsheng Zhang · 2023 · Frontiers in Oncology
  24. Genetic and Epigenetic Alterations in Cancer
    Bin Tean Teh, Eric R. Fearon · 2020 · Elsevier eBooks
  25. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
    Stephen Yiu Chuen Choi, Caroline F. Ribeiro, Yuzhuo Z. Wang, Massimo F. Loda, Stephen R. Plymate, Takuma Uo · 2022 · Biomolecules
  26. Enolase2 and enolase1 cooperate against neuronal injury in stroke model
    Wei Jiang, Lukas Stingelin, Pei Zhang, Xibin Tian, Na Kang, Junqiang Liu, Yilixiati Aihemaiti, Desheng Zhou, Haijun Tu · 2021 · Neuroscience Letters
  27. Metabolite regulates differentiation
    Sophie Trefely, Kathryn E. Wellen · 2018 · Science
  28. Study of Transcriptomic Analysis of Yak (Bos grunniens) and Cattle (Bos taurus) Pulmonary Artery Smooth Muscle Cells under Oxygen Concentration Gradients and Differences in Their Lung Histology and Expression of Pyruvate Dehydrogenase Kinase 1-Related Factors
    Yiyang Zhang, Manlin Zhou, Yuxin Liang, Rui Qiang Li, Lan Zhang, Shuwu Chen, Kun Yang, Haie Ding, Xiao Tan, Qian Zhang et al. · 2023 · Animals
  29. An automated network-based tool to search for metabolic vulnerabilities in cancer
    Luis V. Valcárcel, Edurne San José‐Eneriz, Raquel Ordóñez, Iñigo Apaolaza, Danel Olaverri-Mendizabal, Naroa Barrena, Ana Valcárcel, Leire Gárate, Jesús F. San Miguel, Antonio Pineda‐Lucena et al. · 2024 · Nature Communications
  30. The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues
    Federica Pisaneschi, Yu-Hsi Lin, Paul G. Leonard, Nikunj Satani, Victoria C. Yan, Naima Hammoudi, Sudhir Raghavan, Todd M Link, Dimitra K. Georgiou, Barbara Czakó et al. · 2019 · Molecules
  31. Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells
    Laura González-Sánchez, María Cobos-Fernández, Pilar López‐Nieva, María Villa‐Morales, Konstantinos Stamatakis, Jose Manuel Cuezva, José Luis Marín‐Rubio, Irene Vázquez-Domínguez, Iria González-Vasconcellos, EDUARDO C. SALIDO et al. · 2019 · Carcinogenesis
  32. Enolase Inhibitors as Early Lead Therapeutics against Trypanosoma brucei
    Colm P. Roster, Danielle LaVigne, Jillian E. Milanes, Emily Knight, Heidi D. Anderson, Sabrina S. Pizarro, Elijah M. Harding, Meredith Teilhet Morris, Victoria C. Yan, Cong-Dat Pham et al. · 2023 · Pathogens
  33. Characterization of neural stem cells modified with hypoxia/neuron-specific VEGF expression system for spinal cord injury
    Young In Yun, Je-Heon Oh, Yong Wook Kim, G Kim, M Lee, Y Ha · 2017 · Gene Therapy
  34. SynLeGG: analysis and visualization of multiomics data for discovery of cancer ‘Achilles Heels’ and gene function relationships
    Mark Wappett, Adam Harris, Alexander L. R. Lubbock, Ian Lobb, Simon S. McDade, Ian M. Overton · 2021 · Nucleic Acids Research
  35. The Landscape of Cancer Metabolism as a Therapeutic Target
    Kenji Ohshima · 2025 · Pathology International
  36. Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
    Elisa Mariella, Gaia Grasso, Martina Miotto, Kristi Buzo, Nicole Megan Reilly, Pietro Andrei, Pietro Paolo Vitiello, Giovanni Crisafulli, Sabrina Arena, Giuseppe Rospo et al. · 2024 · Molecular Oncology
  37. S-Score: A Scoring System for the Identification and Prioritization of Predicted Cancer Genes
    Jorge Estefano Santana de Souza, André Faustino Fonseca, Renan Valieris, Dirce Maria Carraro, Jean Y. J. Wang, Richard David Kolodner, SANDRO JOSÉ DE SOUZA · 2014 · PLoS ONE
  38. Eradication of ENO1 -deleted Glioblastoma through Collateral Lethality
    Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, Jeffrey J. Ackroyd, Sunada Khadka, Victoria C. Yan, Dimitra K. Georgiou, Yuting Sun, Rafal J. Zielinski, Theresa Tammy Tran et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  39. Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
    Xinwen Wang, Min Wang, Qijun Lin, Lixin He, Baolin Zhang, Xin Chen, Guan-Hong Chen, Hong Du, Chuandong Lang, Xinsheng Peng et al. · 2024 · Advanced Science
  40. Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration
    Victoria C. Yan, Yasaman Barekatain, Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, Kenisha Arthur, Dimitra K. Georgiou, Yongying Jiang, Yuting Sun, Joseph R. Marszalek et al. · 2023 · ACS Pharmacology & Translational Science
  41. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer
    Junjiang Liu, Yunxia Zhang, Shoubin Li, Fuzhen Sun, Gang Wang, Wei Dong, Tao Yang, Shouyi Gu · 2021 · Oncology Reports
  42. Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets
    Sophia N. Ononye, Wenhao Shi, Vikram B. Wali, Burak Yasin Aktaş, Tingting Jiang, Christos Hatzis, Lajos Pusztai · 2014 · Breast Cancer Research and Treatment
  43. Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
    Verónica Rendo, Snehangshu Kundu, Natallia Rameika, Viktor Ljungström, Richard Svensson, Kimmo Palin, Lauri A. Aaltonen, Ivaylo Stoimenov, Tobias Sjöblom · 2020 · Scientific Reports
  44. Aliphatic amines are viable pro-drug moieties in phosphonoamidate drugs
    Victoria C. Yan, Cong-Dat Pham, Kenisha Arthur, Kristine L. Yang, Florian L. Müller · 2020 · Bioorganic & Medicinal Chemistry Letters
  45. Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
    Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Margus Veanes, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Azhar, Ioanna Tsiara et al. · 2024 · EBioMedicine
  46. The role of synthetic lethality in overcoming cancer therapy resistance: Emerging paradigm and recent advances
    Qingyi Xiong, Jinmei Jin, Jiayi Lin, Bohan Zhang, Yixin Jiang, Zhe Sun, Lijun Zhang, Ye Wu, Guozhi Zhao, Jiang‐Jiang Qin et al. · 2025 · Drug Resistance Updates
  47. Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
    Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Prabhjot Singh Mundi, Yasumichi Kuwahara, Romel Somwar et al. · 2025 · Journal of Clinical Investigation
  48. Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependency
    Shuang Li, Ting Han · 2024 · iScience
  49. Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
    Constanze Schneider, Hermes Spaink, Gabriela Alexe, Neekesh V. Dharia, Ashleigh Meyer, Lucy A. Merickel, Delan Khalid, Sebastian Scheich, Björn Häupl, Louis M. Staudt et al. · 2024 · Cancer Research
  50. Functional buffering via cell-specific gene expression promotes tissue homeostasis and cancer robustness
    Hao-Kuen Lin, Jen‐Hao Cheng, Chia‐Chou Wu, Feng‐Shu Hsieh, Carolyn A Dunlap, Sheng‐hong Chen · 2022 · Scientific Reports
  51. Conditional Covalent Lethality Driven by Oncometabolite Accumulation
    Minervo Perez, Kellie D. Nance, Daniel W. Bak, Supuni Thalalla Gamage, Susana Sarai Najera, Amy N. Conte, William Marston Linehan, Eranthie Weerapana, Jordan L. Meier · 2022 · ACS Chemical Biology
  52. Coessentiality and cofunctionality: a network approach to learning genetic vulnerabilities from cancer cell line fitness screens
    Traver Hart, Clara WT Koh, Jason Moffat · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  53. Expanding the ligandable proteome by paralog hopping with covalent probes
    Yuanjin Zhang, Zhonglin Liu, Marscha Hirschi, Oleg Brodsky, Eric Johnson, Sang Joon Won, Asako Nagata, Matthew D. Petroski, Jaimeen D. Majmudar, Sherry Niessen et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  54. Collateral lethality: A unique type of synthetic lethality in cancers
    Zichen Zhao, Lingling Zhu, Yu Luo, Heng Xu, Yan Zhang · 2024 · Pharmacology & Therapeutics
  55. Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics
    Graeme Benstead-Hume, Sarah K. Wooller, Frances M. G. Pearl · 2017 · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics
  56. Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
    Mariko Sasaki, Daiki Kato, Hiroshi Yoshida, Takafumi Shimizu, Hideaki Ogiwara · 2024 · Cancer Research Communications
  57. A dependency map enhanced with next-generation 3D cancer models
    James V. Neiswender, Samuel Maffa, Lisa Brenan, Dina ElHarouni, Yejie Yun, Isabella Boyle, Kirsty Wienand, Haider Inam, Tate Bertea, Ashley Anderson et al. · 2026 · Nature
  58. Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
    Tim Arnoldus, Alex v. Vliet, Onno B. Bleijerveld, Adriaan F. H. de Groot, Qinglin Piao, Niek Blomberg, Désirée Schatton, Jing Ming Dong, Susan E. van Hal-van Veen, Rolf Harkes et al. · 2025 · Nature Genetics
  59. Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study
    Victoria C. Yan, Kristine L. Yang, Elliot Ballato, Sunada Khadka, Prakriti Shrestha, Kenisha Arthur, Dimitra K. Georgiou, Mykia Washington, Theresa Tammy Tran, Anton H. Poral et al. · 2020 · ACS Medicinal Chemistry Letters
  60. p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)
    Phaik Ju Teoh, Ömer An, Tae‐Hoon Chung, Thamil Selvan Vaiyapuri, Anandhkumar Raju, Michał Marek Hoppe, Sabrina Hui Min Toh, Wilson Wang, Ming Chun Chan, Melissa J. Fullwood et al. · 2022 · Oncogene
  61. High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia
    Lisa F. Lincz, Danielle Z. Theron, Daniel L. Barry, Fiona E. Scorgie, Jonathan R. Sillar, Opelo Sefhore, Anoop Kumar Enjeti, Kathryn Anne Skelding · 2024 · Cancers
  62. Exploiting collateral damage
    Ben Lehner, Solip Park · 2012 · Nature
  63. A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
    Iryna O. Zubovych, Anirudh Sethi, Aditya Kulkarni, Vural Tagal, Michael G. Roth · 2015 · Molecular Cancer Therapeutics
  64. Passenger DNA alterations reduce cancer fitness in cell culture and mouse models
    Christopher D. McFarland, Julia A. Yaglom, Jonathan W. Wojtkowiak, Jacob G. Scott, David L. Morse, Michael Y. Sherman, Leonid A. Mirny · 2015 · bioRxiv (Cold Spring Harbor Laboratory)
  65. Bioreducible Pro-drug Inhibitors of Enolase
    Victoria C. Yan, Kristine Yang, Elliot Ballato, Kenisha Arthur, Dimitra Georgiou, Florian Müller · 2020 · ChemRxiv
  66. Shape of population interfaces as an indicator of mutational instability in coexisting cell populations
    Clarisa E Castillo, Maxim O. Lavrentovich · 2020 · Physical Biology
  67. Robust detection of oncometabolic aberrations by 1H–13C heteronuclear single quantum correlation in intact biological specimens
    Yasaman Barekatain, Victoria C. Yan, Kenisha Arthur, Jeffrey J. Ackroyd, Sunada Khadka, John de Groot, Jason T. Huse, Florian L. Müller · 2020 · Communications Biology
  68. Identification of putative actionable alterations in clinically relevant genes in breast cancer
    Pushpinder Kaur, Tania Bibiana Porras, Anthony Colombo, Alexander Ring, Janice M. Lu, Irene M. Kang, Julie E. Lang · 2021 · British Journal of Cancer
  69. Bourgeoning Cancer Targets
    Priyanka Kriplani · 2022 · Recent Patents on Anti-Cancer Drug Discovery
  70. VRK1 is required in VRK2-methylated cancers of the nervous system
    Jonathan So, Nathaniel W. Mabe, Bernhard Englinger, Sydney M. Moyer, Maria C. Trissal, Joana Graca Marques, Jason J. Kwon, Brian H. Shim, Eshini Panditharatna, Daeun Jeong et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  71. Silencing PIM1 inhibits ENO1-induced AKT activation and attenuates fibrillogenesis during spinal cord injury-induced skeletal muscle atrophy
    Xiao Hong Yu, Jiang Cao, Binyu Wang, Jiaju Fu, Jingcheng Liu, Tao Sui, Zi Wang, Chaoqin Wu, Jie Chang, Xiaojian Cao et al. · 2025 · Journal of Biological Chemistry
  72. Transcriptional rewiring in cancer driven by POLR2A/RPB1: mechanistic insights, non-coding RNA crosstalk, and therapeutic opportunities
    Adrian Szczepaniak, Kinga Jaskuła, Marta Zielińska, Jakub A. Godlewski · 2025 · Frontiers in Pharmacology
  73. Multiple Myeloma Cells with Increased Proteasomal and ER Stress Are Hypersensitive to ATX-101, an Experimental Peptide Drug Targeting PCNA
    Camilla Olaisen, Lisa Marie Røst, Animesh Sharma, Caroline Krogh Søgaard, Tiffany T. Khong, Sigrid Berg, Mi Jang, Aina Nedal, Andrew G Spencer, Per Bruheim et al. · 2024 · Cancers
  74. Incomplete paralog compensation generates selective dependency on TRA2A in cancer
    Amanda R. Lee, Anna Tangiyan, Isha Singh, Peter S. Choi · 2025 · PLoS Genetics
  75. Amoxicillin Haptenation of α-Enolase is Modulated by Active Site Occupancy and Acetylation
    Juan M. González-Morena, Francisco J. Sánchez-Gómez, Yolanda Vida, Ezequiel Pérez‐Inestrosa, Maria Luisa Salas, Maria Isabel Montañez, Alessandra Altomare, Giancarlo Aldini, Marı́a A. Pajares, Dolores Pérez‐Sala · 2022 · Frontiers in Pharmacology
  76. Generation and Validation of an Anti-Human PANK3 Mouse Monoclonal Antibody
    Sunada Khadka, Long Vien, Paul G. Leonard, Laura C. Bover, Florian L. Müller · 2022 · Biomolecules
  77. Anticancer Opportunity Created by Loss of Tumor Suppressor Genes
    Xue Hui-Ying, Dahong Zhang, Li-Juan Ji, Xiaojie Lu · 2015 · Technology in Cancer Research & Treatment
  78. Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity
    Xiaonan Zhang, Ece Akcan, Mário S. P. Correia, Natallia Rameika, Snehangshu Kundu, Ivaylo Stoimenov, Verónica Rendo, Anna Eriksson, Martin Haraldsson, Daniel Globisch et al. · 2022 · Biochemical Pharmacology
  79. Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss
    Tao Zhou, Huayun Yan, Dandan Yin, Yun Kai Deng, Huancheng Fu, Zichen Zhao, S. Li, Xiaoxi Lu, Yiqi Deng, Hai‐Ning Chen et al. · 2025 · MedComm
  80. Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer
    Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires, Helena N. Jenkins, Charlotte B. Pratt, Eden N. Gordon, Shan-Chuan Zhao, Ashley H. Choi, Samuel R. Meier, Tenzing Khendu et al. · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  81. Oxidative stress and cancer metabolism: From pathogenesis to therapeutic opportunities
    Tejas Girish Agnihotri, Shyam Sudhakar Gomte, Biswajit Rout, Vasu Peddinti, Sandeep Kr Maharana, Devaraj Yallappa, Aakanchha Jain · 2025 · Elsevier eBooks
  82. Collateral metabolic vulnerabilities unveiled by loss of isozyme diversity in breast cancer
    Rui Ding, Tian‐Jian Yu, Yi‐Zhou Jiang, Yi Xiao, Zhi‐Ming Shao · 2025 · Genome Medicine
  83. Context-dependent synthetic lethality — an emerging precision therapeutic approach
    Liang Chang, Katharin L. Shaw, Francisca Vázquez, William R. Sellers · 2026 · Nature reviews. Cancer
  84. Impact of accumulated alterations in driver and passenger genes on response to radiation therapy
    Yuji Seo, Keisuke Tamari, Yutaka Takahashi, Kazumasa Minami, Fumiaki Isohashi, Осаму Сузукі, Iori Sumida, Kazuhiko Ogawa · 2020 · British Journal of Radiology
  85. Intrinsic deletion at 10q23.31, including the PTEN gene locus, is aggravated upon CRISPR-Cas9–mediated genome engineering in HAP1 cells mimicking cancer profiles
    Keyi Geng, Lara G. Merino, Raül G. Veiga, Christian Sommerauer, Janine Epperlein, Eva Karina Brinkman, Claudia Kutter · 2023 · Life Science Alliance
  86. SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss
    Xinqi Xi, Ling Liu, Natasha Tuano, Julien Tailhades, Dmitri Mouradov, Jason A. Steen, Oliver M. Sieber, Max J. Cryle, Tú Nguyen‐Dumont, Eva Segelov et al. · 2025 · Proceedings of the National Academy of Sciences
  87. Back to the Future: Therapeutic Targeting of Cancer Cell Metabolism
    Raymond Gilmour, Susana Velasco · 2017 · SLAS DISCOVERY
  88. Investigation of the Effects of Apigenin, a Possible Therapeutic Agent, on Cytotoxic and SWH Pathway in Colorectal Cancer (HT29) Cells
    Mustafa Çiçek, Velid Ünsal, Arif Emre, Adem Doğaner · 2021 · Advanced Pharmaceutical Bulletin
  89. Genomic instability establishes dependencies on acquired gene regulatory networks: A novel role of p62 in myeloid malignancies with del(5q)
    Jing Fang, Daniel T. Starczynowski · 2015 · Molecular & Cellular Oncology
  90. Principles of Medical Oncology
    Apostolia Maria Tsimberidou, Robert C. Bast, Fadlo Raja Khuri, John C. Byrd · 2022 · Holland‐Frei Cancer Medicine
  91. A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer
    Verónica Rendo, Michaël Schubert, Nicholas Khuu, Maria F. Suárez Peredo Rodríguez, Kaimeng Huang, Michelle L. Swift, Yizhou Joseph He, Johanna Zerbib, Ross Smith, Jonne A. Raaijmakers et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  92. Passenger deletions create cancer-specific Achilles heel
    Alexandra Flemming · 2012 · Nature Reviews Drug Discovery
  93. Discovery of MTA-cooperative PRMT5 Inhibitors
    John P. Maxwell, Kevin M. Cottrell, K. Briggs · 2024 · Royal Society of Chemistry eBooks
  94. 1p/19q codeletion induces targetable and imageable vulnerabilities in glucose metabolism in oligodendrogliomas
    Suresh Udutha, Georgios Batsios, Céline Taglang, Anne Marie Gillespie, Pavithra Viswanath · 2026 · Neuro-Oncology
  95. IGF2BP3 promotes glycolysis of osteosarcoma stem cells by reading RNA m⁶A to stabilize ENO1 and promote malignant biological behavior of osteosarcoma
    Binglun Zhang, Xue Ren, Bo Wang, Yuting Wang, Delong Zhang, Fanhe Meng · 2026 · Cell Biology and Toxicology
  96. Alive failures behind the windows of cancer therapy
    Muhammad Torequl Islam · 2017 · International Journal of Medicine
  97. Cancer metabolism
    Tomas Koltai, Stephan J. Reshkin, Salvador Harguindey · 2020 · Elsevier eBooks
  98. Correction: Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer
    Florian L. Müller, Simona Colla, Elisa Aquilanti, Veronica E. Manzo, Giannicola Genovese, Jaclyn Lee, Daniel L. Eisenson, Rujuta Narurkar, Pingna Deng, Luigi Nezi et al. · 2015 · Nature
  99. Improving platinum-based treatments for advanced non-small cell lung cancer
    Ada W.Y. Leung · 2016 · cIRcle (University of British Columbia)
  100. LncRNA ZFAS1 contributed to irradiation resistance in nasopharyngeal carcinoma by inhibiting hsa-miR-7-5p/ENO2
    Jiaojiao Peng, Feng Liu, Hong Zheng, Qi Wu, Shixi Liu · 2020